Background. Policies mandating the use of lower cost biosimilars in patients with
inflammatory bowel disease (IBD) have created concerns for patients who prefer their …

Objective Uptake of biosimilars has been suboptimal in North America. This study was
undertaken to quantify the impact of various policy interventions (namely, new start and …

Introduction A period of exclusivity for the first generics, as part of the patent linkage system,
was established in South Korea to provide an economic incentive for early generic entry …

Rheumatic diseases are becoming increasingly prevalent in Canada, and its associated
strain on the healthcare system is expected to increase over the next decades. Furthermore …

Background Rheumatoid arthritis (RA) is a major global health problem and a neglected
disease in many developing countries. Health care spending is low in these countries and …

Background Health systems across countries have used different policy measures (eg price
discounts, tendering, mandating switches) to encourage the introduction of biosimilars but …

Background Early 2020, short supply of hydroxychloroquine sulfate (HCQ)–then claimed as
effective for treatment of COVID-19 in several countries-raised significant concerns for those …

BACKGROUND Despite representing less than 2% of prescriptions, biologics accounted for
nearly three of every ten dollars spent on prescribed medicines in Canada in 2018. Similar …

In December 2022, the Government of Ontario announced that the current Ontario Health
Insurance Plan (OHIP) will no longer cover specific biologic medications, only biosimilar …

Anticancer biosimilar use is rising but significant potential savings remain unrealized@
alison_mcclean@ ChrisLuPhD